Two large trials provide further evidence that one dose of HPV vaccine could prevent the majority of cervical cancers

A single dose of the bivalent human papillomavirus (HPV) vaccine (Cervarix®, GlaxoSmithKline group of companies) may offer a similar level of protection against HPV-16/18 infections, which cause about 70% of cervical cancers, as the current two- and three-dose schedules, according to new research combining data from two large phase 3 trials.